

# Theranova 500

DESIGNED FOR:

**HDx**

MEMBRANE:

**MCO** [PAES/PVP, BPA-free]

## HDx THERAPY ENABLED BY THERANOVA

The HDx therapy (expanded HD) is the next evolution in hemodialysis, as it effectively targets the removal of large middle molecules.<sup>1</sup> Indeed, many of them are linked to the development of inflammation, cardiovascular disease, and other co-morbidities in dialysis patients.<sup>2</sup> Not only can HDx therapy provide HDF performance and beyond in the removal of conventional middle and large middle molecules, it does so using regular HD workflow and infrastructure.<sup>3</sup>

The HDx therapy is enabled by the **Theranova**\* dialyzer series, featuring an innovative membrane design that combines a higher permeability than regular high-flux dialyzers with effective selectivity for large proteins.<sup>4,5</sup>

## HDF PERFORMANCE AND BEYOND, AS SIMPLE AS HD<sup>3</sup>

- Markedly greater clearances and intradialytic reduction ratios for middle molecules than regular HD – at ordinary blood flow rates
- Equivalent removal of small and conventional middle molecules to high-volume HDF – Greater removal possible for large middle molecules
- Controlled albumin removal to between 1 and 4 grams per session<sup>3</sup>
- Compatible with any HD monitor<sup>6,7</sup> and with standard dialysis

## WITH BAXTER'S LATEST DIALYZER INNOVATION, COMING CLOSER TO THE NATURAL KIDNEY<sup>4,5</sup>

- High permeability to large middle molecules
- Effective selectivity by size exclusion
- Augmented internal filtration
- Similar retention of endotoxins as other dialysis membranes of the same material<sup>8</sup>



\* Do not use **Theranova** dialyzers in HDF or HF mode

# Theranova 500 Specifications

MATERIALS	THERANOVA 500
Membrane	Medium Cut Off Polyarylethersulfone and Polyvinylpyrrolidone blend BPA-free
Potting	Polyurethane (PUR)
Housing	Polycarbonate (PC)
Gaskets	Silicone rubber (SIR)
Protection caps	Polypropylene (PP)
Sterilization	Steam (inside-out)
Sterile barrier	Tyvek

## SPECIFICATIONS

UF-Coefficient (mL/h*mmHg)*	59
KoA urea*	1630
Blood Compartment volume (mL)	105
Minimum recommended priming volume (mL)	300
Maximum TMP (mmHg)	600
Recommended Q <sub>B</sub> (mL/min)	250-600
Storage conditions	<30°C (or <86°F)
Units per box	24
Gross/net weight (g)	246/190

## MEMBRANE

Effective Membrane Area (m <sup>2</sup> )	2.0
Fiber inner diameter (µm)	180
Fiber wall thickness (µm)	35

## SIEVING COEFFICIENTS\*

Vitamin B12 (1,4 kDa)	1.0
Inulin (5,2 kDa)	1.0
β <sub>2</sub> -microglobulin (11,8 kDa)	1.0
Myoglobin (17 kDa)	0.9
Albumin (66,4 kDa)	0.008

\* According to EN 1283/ISO 8637:

- UF-Coefficient: measured with bovine blood, Hct 32%, Pct 60g/L, 37°C
- KoA urea: calculated at Q<sub>B</sub>=300 mL/min, Q<sub>D</sub>=500mL/min, UF=0 mL/min
- Sieving coefficients: measured with human plasma, Q<sub>B</sub>=300 mL/min, UF=60 mL/min
- Clearances In-Vitro: measured at UF=0 mL/min, ±10% [±20% Cyt. C, ±30% Myo.]

CLEARANCES IN VITRO (mL/min)*	THERANOVA 500
<b>Urea (60 Da) (Q<sub>B</sub>-Q<sub>D</sub>, mL/min)</b>	
200/500	199
300/500	285
400/500	351
400/800	381
500/800	454
<b>Phosphate (95 Da)</b>	
200/500	194
300/500	267
400/500	320
400/800	354
500/800	413
<b>Creatinine (113 Da)</b>	
200/500	196
300/500	274
400/500	331
400/800	365
500/800	428
<b>Vitamin B12 (1.4 kDa)</b>	
200/500	169
300/500	215
400/500	249
400/800	280
500/800	317
<b>Inulin (5.2 kDa)</b>	
200/500	139
300/500	170
400/500	193
400/800	216
500/800	241
<b>Cytochrome C (12 kDa)</b>	
200/500	128
300/500	155
400/500	175
400/800	196
500/800	217
<b>Myoglobin (17 kDa)</b>	
200/500	110
300/500	130
400/500	147
400/800	163
500/800	180

1. Ronco C, et al. *The rise of Expanded Hemodialysis*. Blood Purif 2017; 44:1-VIII.
2. Hutchison CA, et al. *The Rationale for Expanded Hemodialysis Therapy (HDx)*. Contrib Nephrol 2017; 191:142-52.
3. Kirsch AH, et al. *Performance of hemodialysis with novel medium cut-off dialyzers*. Nephrol Dial Transpl 2017; 32(1):165-72.  
Data was obtained with TH400 and may be applied to TH500 due to similarities in membrane and design.
4. Boschetti-de-Fierro A, et al. *MCO membranes: Enhanced Selectivity in High-Flux Class*. Scientific Reports 2015; 5:18448.
5. Zweigart C, et al. *Medium cut-off membranes – closer to the natural kidney removal function*. Int J Artif Organs 2017; 40(7):328-334.
6. Baxter. Data on file. *Theranova Limited Controlled Distribution Report*. 2016.
7. Baxter. *Theranova 400/500 Instructions For Use*. N50 648 rev 003, 2017-05-29.
8. Schepers E, Glorieux G, Elout S, et al. *Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up*. BMC Nephrology. 2018; 19:1.

For further information  
visit [hdxttheranova.com](http://hdxttheranova.com):



The products meet the applicable provisions of Annex I (Essential Requirements) and Annex II (Full quality assurance system of the Council Directive 93/42/EEC of 14 June 1993, amended by Directive 2007/47/EC)

For safe and proper use of the device, please refer to the Instructions for Use

CE 0086